Metabolic cofactor and antioxidant · Fact sheet
Alpha-lipoic acid
Also known as ALA · Thioctic acid
Alpha-lipoic acid has human research on diabetic nerve symptoms. Short-term symptom improvement does not establish nerve regeneration, and a large long-term trial missed its primary endpoint.
What is Alpha-lipoic acid?
Alpha-lipoic acid participates in cellular energy metabolism. It is different from alpha-linolenic acid, a fatty acid also abbreviated ALA.
Benefits people look for
Nerve pain, glucose control, antioxidant effects, and healthy aging are common interests. Diabetic neuropathy findings cannot be generalized to every cause of nerve symptoms.
What the evidence supports
- Short-term randomized evidence supports improvement in some diabetic neuropathy symptoms.
- Long-term findings do not establish that ALA reverses nerve damage or prevents disability.
All research areas
- Diabetic polyneuropathy
- Neuropathic symptoms
- Metabolic biomarkers
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Nausea, vomiting, and vertigo increased with exposure in the short-term trial.
- NATHAN 1 reported more serious adverse events in the ALA group; the imbalance does not establish that every event was caused by ALA.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Moderate human evidenceThe five-week SYDNEY 2 study enrolled 181 adults with diabetic polyneuropathy. The four-year NATHAN 1 study enrolled 460 and did not significantly improve its primary combined endpoint, despite some favorable secondary findings.
Selected research to read
181-person, five-week randomized trial with gastrointestinal and dizziness effects.
460 participants; primary endpoint not significant and secondary findings require context.
FDA approval & research status
Alpha-lipoic acid has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.
No FDA-approved use is documented in the records summarized on this page.
Supplement research is not FDA drug approval
Alpha-lipoic acid has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Long-term effects on disability or nerve regeneration
- Applicability to non-diabetic neuropathy
- Safety and interactions across preparations
The takeaway
Long-term findings do not establish that ALA reverses nerve damage or prevents disability.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedSYDNEY 2: alpha-lipoic acid and diabetic neuropathy symptoms
181-person, five-week randomized trial with gastrointestinal and dizziness effects.
- 2pubmedNATHAN 1: four-year alpha-lipoic acid trial
460 participants; primary endpoint not significant and secondary findings require context.
- 3fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.